Informasjon/Twitter/Artikler/Børsmeldinger


Ny klinikk oppført på Cysview i ettermiddag.

**Blessing Health System 02.03.20

Broadway at 11th Street, PO Box 7005, Quincy, IL 62305

I tillegg er følgende oppført hittil i 2020:
**Perlmutter Cancer Center at NYU Langone Health | NYU Langone Urology Associates 27.02.20

222 East 41st Street New York, NY 10017

**Sharp Memorial Hospital 24.02.20

7901 Frost Street, San Diego, CA 92123

**Cleveland Clinic Akron 05.02.20

1 Akron General Ave., Akron, OH 44307

**University of Washington 27.01.20

1959 NE Pacific St, Seattle, WA 98195

**University of Florida Department of Urology 15.01.20

1600 SW Archer Road, Room N216, Gainesville, FL 32610

**Beth Israel Deaconess Medical Center 13.01.20

330 Brookline Ave., Rabb 440, Boston, MA 02215

Etter flere måneder med ombygging av HEXVIX.COM siden har den nå kommet ut i ny drakt.

http://hexvix.com/

Selskapet svarer idag at responsivt design kommer, men har ikke tidspunkt for dette.

Ny klinikk oppført på Cysview.

Dartmouth-Hitchcock Medical Center
1 Medical Center Drive, Lebanon, NH 03766
https://www.dartmouth-hitchcock.org/
Redigert 11.03.2020 kl 14:40 Du må logge inn for å svare

Ny aksjonærliste hentet ut idag(gjeldende til og med tirsdag) Den hensyntar da selvsagt ikke HS sitt salg av 220k igår.

Men største endringer er som følger:

The Bank of NY +130k

Nordnet Liv -35k

JPM Sec +80k til 177k INN

AS Skarv UT

FYI. (publisert på fb gruppen)

God mandags morgen Godtfolk!

I disse tider hvor usikkerheten rår verden over sitter mange(sikkert de fleste) og lurer på hvordan man skal forholde seg og hva man skal gjøre. Skal man kjøpe, selge, kjøpe mer, selge mer, dumpe eller all inn. Vanskelige valg selvsagt, for alle sammen. Jeg har respekt for alle uansett hvilket valg man faller ned på, for fasit er det pt ingen som sitter på.

I løpet av helgen har jeg oppfordret CEO Schneider til å komme ut med en oppdatert status rapport så snart det lar seg gjøre hvor man sier noe om hvordan situasjonen eventuelt påvirker Photocure og om hvordan selskapet ser på veien videre.

I urolige tider kan det aldri komme nok informasjon. Så får vi se om Schneider tar oppfordringen.

Ny topp 20 liste(gjeldende til og med torsdag) viser at HS som kjent solgte 220k.

I tillegg følgende endringer av betydning.

The Bank of NY +65k

Barclays Capital Sec. + 156k INN

The Bank of NY + 11k

Danske Bank + 11k

Nordnet Bank + 11k

Myrlid - 60k

Clearstream Banking UT

Vinterstua UT

Skjer mye på aksjonærlistene i Pho i disse dager. Vedlagt de største endringene siden Pho sin offisielle Topp 20 liste lagt ut på mandags morgen.

1 High Seas 700k -1,520k

4 The Bank of NY 502,528 +115k

5 Tycoon Industrier(ØSS) 494,488 + 494,488

12 Apollo Asset(Fredly) 300k +300k

13 Kristianro(ESS) 276,772 +150k

18 KLP AksjeNorge Indeks 215,072 -15k

22 Societe Generale 158,106 +158,106

28 JP.Morgan Sec 144,024 + 144,024

In addition, Cevira, a photodynamic drug combination product that is being developed for the non-surgical treatment of cervical precancerous lesions, which is being developed by Yahong Pharmaceutical , will also start a China-US-Europe International Multi-Centre III clinical trial, mainly for Chinese patients. This product is used to treat patients with a high-grade cervical squamous intraepithelial lesion (HSIL) confirmed histopathologically by the histopathology of 18 years and older .

http://www.myzaker.com/article/5e796779b15ec0245c4b06e7/?fbclid=IwAR3kgkufSJPZx83ziEu37FsQ5Vv7t0VPuH935gAPZZsnsD3r83gKiqKlCek

Nytt fra Asieris igår.
Finner den dessverre bare i et word dokument, Cevira er omtalt litt nedenfor.
Finnes også på kinesisk. http://www.asieris.cn/index.php/content/186?fbclid=IwAR2ybGL08Srk8kFn8CHW6oziIzlpLvjbMOHJosOFv-Rnw9luJPtz5y_yNZw



Asieris 24-03-2020
Yahong Pharmaceutical announces the completion of Series C financing to accelerate the development of the world's first innovative drug
Time: 2020-03-24
Shanghai, China, March 24, 2020-Yahong Pharmaceutical Technology Co., Ltd. ("Yahong Pharmaceutical") today announced the completion of Series C financing, raising hundreds of millions of yuan in capital, and the C + round of financing will also be completed in the near future. This round of financing was led by Yanyuan Innovation Capital, followed by investment institutions such as Interchina Venture Capital and Yifeng Capital. Round B investment institutions Beijing Longpan and Kaitai Capital continued to invest in this round through cooperative funds. The funds raised will be used to support the company's multiple independent research and development projects.

The key project of Yahong Pharmaceuticals APL-1202 is the national “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan for Major New Drug Creation Projects”. It is the world's first innovative drug for oral treatment of non-muscle invasive bladder cancer that has entered registered clinical development. At present, the standard drug treatment method for preventing recurrence of non-muscle invasive bladder cancer after surgery is bladder infusion chemotherapy or BCG. The whole process is very painful and the adverse reactions are serious. APL-1202, as a new oral antitumor mechanism, is convenient, painless, and harmless to the urethra. It will help patients avoid or delay the fate of total bladder resection. APL-1202 has completed the phase III clinical trial of all patients in China, and also completed the phase I clinical trial in the United States. The phase II clinical trial in the United States is about to start.

Cevira®, a photodynamic drug combination product for non-surgical treatment of cervical precancerous lesions, which is being developed by Yahong Pharmaceutical, will also start the China-US-Europe International Multi-Center III clinical trial, mainly for Chinese patients, in 2020. Cevira® is targeted to treat patients 18 years of age and older who have a histopathologically proven high-grade cervical squamous intraepithelial lesion (HSIL). The current standard treatment for these patients is surgery. The most common treatments include cervical circular resection (LEEP / LLETZ) and cold-knife cone resection (CKC). However, these surgical treatments have adverse reactions, including bleeding. , Infection, cervical organic damage caused by a series of subsequent effects on fertility, such as premature delivery, abortion and so on. Therefore, Cevira® will provide a new treatment option for Chinese and global patients, so that some patients can avoid the pain and side effects of surgical treatment, especially the risk of future pregnancy. Cevira® has also won the Fierce Life Science Innovation Award with the international reputation of the best medical device innovation award 2019.

Yahong Pharmaceutical's other research project APL-1501 also belongs to the country's "13th Five-Year Plan for Major New Drug Development". This project mainly focuses on the treatment of multi-drug resistant infections. Compared to traditional antibiotics, APL-1501 has a new antibacterial mechanism and has good bactericidal activity against broad-spectrum Gram-positive and negative drug-resistant bacteria. And it has shown good efficacy in animal models of systemic multidrug resistance infection. APL-1501 is of great significance in addressing the severe challenge of no drug treatment after multidrug resistance infections facing the world, especially in China. In addition to multiple independent research and development of new drug projects and exclusive technology platforms, Yahong Pharmaceutical also negotiates with many domestic and foreign biopharmaceutical companies to develop cooperation in China and overseas markets.

Dr. Pan Ke, co-founder and CEO of Yahong Pharmaceutical, said: "This Series C financing led by Yanyuan Innovation Capital has provided strong support for the subsequent development of Yahong Pharmaceutical, and we are very grateful to investors for their support. Recognition of Rainbow Pharmaceutical's R & D strategies, projects and technologies. After ten years of accumulation, 2020 will be a year of rapid development for Yahong Pharmaceutical, and many projects will soon complete clinical trials or apply for new drug certificates. Yahong Pharmaceutical will also embark on a new The journey from the R & D company to the pharmaceutical company integrating research, production and sales will bring innovative therapeutic drugs and better treatment methods to more patients as soon as possible. "

Yanyuan Innovation Capital has always been adhering to the concept of value investment. In recent years, it has vigorously deployed life and health, especially biomedicine, medical equipment and other sub-sectors. Liu Zeng, President of Yanyuan Innovation Capital, commented, "Yahong Pharmaceuticals has a rich product pipeline layout and unique technology platform, and has breakthrough potential in its focus on the field of urogenital tumors. We believe that Dr. Pan, led by Hong The team can fully combine the advantages of domestic and foreign technologies, talents, capital and markets to make Yahong Pharmaceutical into a leading pharmaceutical company at home and abroad. We are glad to participate in the growth of Yahong together. "

Since its establishment in 2010, Yahong Pharmaceutical has been adhering to the belief of "improving human health and making life more dignified", and is committed to becoming the most innovative and influential pharmaceutical company in the field of focus and respect and trust. Yahong Pharmaceutical's business is located in Shanghai, Beijing, Jiangsu Taizhou Medical City and the United States.At the same time, it has established a research and development center in Shanghai and has established an international professional R & D technical team, focusing on anti-tumor and related diseases of the urogenital system. Global innovative drug research and development. Yahong Pharmaceutical's previous rounds of A and B financing have been led by well-known venture capital institutions such as Taifu Capital and Beijing Longpan.



About Yahong Pharmaceutical
Yahong Pharmaceutical was established in March 2010 in China Medical City, Taizhou City, Jiangsu Province, and established a research and development center in Shanghai. It is a global innovative drug research and development company focusing on anti-tumor and related diseases of the urogenital system in China. Yahong Pharmaceutical is determined to become the most innovative and influential pharmaceutical company in the field of focus, most respectable and trustworthy. The company focused on the urogenital field and quickly established a leading position in this field and carried out a deep strategic layout. Yahong Pharmaceutical fully explores the global value of first-in-class new drugs with independent research and development and breakthrough therapeutic potential, while introducing new drugs that are already in the late stage of development overseas or have been launched into the Chinese market, improving product pipeline diversification and synergy, Quickly establish a leading position in the domestic market.

About Yanyuan Innovation Capital
Yanyuan Innovation Capital, formerly known as "Yanyuan Capital Group", was founded in June 2010. With the support of the Peking University Science and Technology Development Department, it is a high-tech enterprise jointly established by Peking University alumni who are engaged in venture capital investment and university technology achievement transformation. Investment and capital operation platform, currently has three major business segments of equity investment, securities investment, listed company cooperation and mergers and acquisitions reorganization. The headquarters is located in Beijing. It was established in Ningbo, Zhejiang in 2015, Hangzhou office in 2018, and Shanghai office in 2019. Close to 70 people. The overall management scale of venture capital funds, industrial funds, parent funds, and securities funds managed directly or indirectly by Yanyuan Innovation Capital has exceeded RMB 6 billion; 5 private equity fund managers have been registered, and more than 30 private equity funds have been registered Over 50 foreign investment projects, and more than 10 companies have been listed and declared to be listed in the past three years. The investment fields cover such industries as biomedicine, advanced manufacturing, and new-generation information technology. In 2019, there were 2 companies in the biomedical field in the invested companies listed on the science and technology board, of which Zeyu Pharmaceutical led by Yanyuan Innovation Capital was the first company in the science and technology board to declare and list on the fifth set of standards. Unprofitable biopharmaceutical company.

About Interchina Ventures
Shenzhen Guozhong Venture Capital Management Co., Ltd. is a private equity investment agency specializing in the management of venture capital investment trusts. Interstate Venture Capital advocates the investment concept of research first, combining investment with research. Guide the investment through in-depth research on the industry chain, focus on investment opportunities in strategic emerging industries, and focus on investing in outstanding companies in the three major areas of technological innovation, biomedical health, and TMT.

About Yifeng Capital
Yifeng Capital is a professional institution focusing on VC and PE investment in biomedicine. It uses a global perspective to deeply d